Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence Nov 25, 2024 Media Release Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analys...
顶/踩数: 0/0 收藏人数: 0 评论次数: 0 文档热度: 文档分类: 待分类 系统标签: voltarennovartisretardodersieeinnahme Seite1((NovartisLogo))Gebrauchsinformation:InformationfürdenAnwenderVoltaren®100mgretardRetardtablettenZurAnwendungbeiErwachsenenWirkstoff:Diclofenac-NatriumLesenSiediegesamtePackungsbeilagesor...